Advanced Therapeutics最新文献

Issue Information (Adv. Therap. 9/2026) 发行信息（第9/2026号公告）

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-01 DOI: 10.1002/adtp.70168

引用次数: 0

Advancing Preclinical Oncology: Next-Generation Mouse Models for Decoding Tumor Progression and Metastasis 推进临床前肿瘤学：解码肿瘤进展和转移的下一代小鼠模型

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-09-01 DOI: 10.1002/adtp.70167

Abhishek Sharma, Aman Kumar, Preeti Patel, Balak Das Kurmi

{"title":"Advancing Preclinical Oncology: Next-Generation Mouse Models for Decoding Tumor Progression and Metastasis","authors":"Abhishek Sharma, Aman Kumar, Preeti Patel, Balak Das Kurmi","doi":"10.1002/adtp.70167","DOIUrl":"https://doi.org/10.1002/adtp.70167","url":null,"abstract":"<div>\u0000 \u0000 <p>Next-generation mouse models have transformed preclinical oncology by enabling detailed study of tumor initiation, progression, immune interactions, and metastasis. Traditional systems lacked tumor heterogeneity and immune relevance. Advanced platforms such as genetically engineered mouse models (GEMMs), humanized mice, patient-derived xenografts (PDXs), and organoid-based models provide genetic accuracy, patient-specific biology, and functional immune environments. Recent developments, such as intravital imaging, lineage tracing, multi-omics, and artificial intelligence (AI), have further improved the understanding of tumor dynamics and therapeutic response. Notwithstanding these major improvements, there are no currently available mouse models that can effectively recapitulate the complexity, latency, organ-specific spread, and tumor–microenvironment interactions that are seen in human metastasis. This means that there is a need for further optimization and enhancement of the preclinical models to make them more translatable and relevant. Together, these new-generation models offer a unique opportunity for the transition from experimental research to clinical oncology and for precision medicine and metastasis-oriented cancer research.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 9","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148862452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venom-Derived Bioactive Peptides: From Toxins to Therapeutics 毒液衍生的生物活性肽：从毒素到治疗

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-08-13 DOI: 10.1002/adtp.70166

Eldho Sabu, Othman Al Musaimi

{"title":"Venom-Derived Bioactive Peptides: From Toxins to Therapeutics","authors":"Eldho Sabu, Othman Al Musaimi","doi":"10.1002/adtp.70166","DOIUrl":"https://doi.org/10.1002/adtp.70166","url":null,"abstract":"<p>Venoms are complex biochemical mixtures composed of diverse bioactive components, including proteins, enzymes, small molecules, and peptides. Among these, venom-derived peptides have been evolutionarily optimized to interact with biological targets with exceptional potency and selectivity. Although historically regarded solely as toxic substances, these peptides have increasingly been recognized as valuable templates for therapeutic development. This review examines the structural and biochemical properties of venom-derived peptides, as well as their molecular targets, with particular emphasis on their applications in pain management and cardiovascular disorders. Key milestones in venom-based drug discovery are highlighted, from the approval of captopril in 1981 to more recent peptide candidates such as Hi1a and leptucin. Despite notable successes, the clinical translation of venom peptides remains constrained by challenges related to their physicochemical properties, including stability, bioavailability, and delivery. Emerging strategies aimed at overcoming these limitations are also discussed, underscoring advances in peptide engineering and drug delivery technologies. Overall, this review highlights the significant therapeutic potential of venom-derived peptides and their expanding role in the development of novel treatments for a wide range of pathological conditions.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70166","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148753487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Challenging the Status Quo: Standardisation, Regulation and the Rise of 3D In Vitro Models for a More Humane and Predictive Future in Healthcare 挑战现状：标准化、监管和3D体外模型的兴起，为医疗保健行业带来更人性化和可预测的未来

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-08-06 DOI: 10.1002/adtp.70164

Priscila Melo

{"title":"Challenging the Status Quo: Standardisation, Regulation and the Rise of 3D In Vitro Models for a More Humane and Predictive Future in Healthcare","authors":"Priscila Melo","doi":"10.1002/adtp.70164","DOIUrl":"https://doi.org/10.1002/adtp.70164","url":null,"abstract":"<p>For decades, biomedical research has relied on two-dimensional (2D) cell cultures and animal models to study human biology and develop new therapeutics. While these systems have been instrumental in advancing science, their limitations in capturing the complexity and variability of human physiology are increasingly evident. As therapeutic strategies become more sophisticated and personalised, the need for more predictive and human-relevant models is becoming critical. In this Perspective, it is argued that three-dimensional (3D) in vitro models such as organoids, bioprinted tissues, and microphysiological systems offer a necessary shift in how we approach disease modelling and drug development. These systems more accurately replicate tissue architecture, cellular interactions, and dynamic environments, yielding more meaningful insights into human biology. At the same time, they support a transition toward more ethical research practices by reducing reliance on animal testing. Discussing the scientific advances enabling these models, the growing regulatory and policy support for their adoption, and the key challenges that remain, is paramount. Addressing these barriers will require coordinated efforts across disciplines and sectors. The delayed adoption of these systems is also shaped by cultural inertia within the scientific and industrial ecosystems, where established methodologies still dominate due to familiarity, infrastructure and insufficient training.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70164","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148752825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Issue Information (Adv. Therap. 8/2026) 发布信息（ad . Therap. 8/2026）

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-29 DOI: 10.1002/adtp.70163

引用次数: 0

Molecular Docking-Guided Engineering of TPGS/Tween 80 Mixed Micelles for the Intranasal Delivery of Paliperidone Palmitate TPGS/Tween 80混合胶束的分子对接工程用于帕利哌酮棕榈酸酯的鼻内递送

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-29 DOI: 10.1002/adtp.70162

Poorva Maske, Rati Kailash Prasad Tripathi, Singdha Das Mandal, Pranav Shah, Nimeet Desai, Manisha Lalan

{"title":"Molecular Docking-Guided Engineering of TPGS/Tween 80 Mixed Micelles for the Intranasal Delivery of Paliperidone Palmitate","authors":"Poorva Maske, Rati Kailash Prasad Tripathi, Singdha Das Mandal, Pranav Shah, Nimeet Desai, Manisha Lalan","doi":"10.1002/adtp.70162","DOIUrl":"https://doi.org/10.1002/adtp.70162","url":null,"abstract":"<p>Poor aqueous solubility severely limits the brain delivery of paliperidone palmitate (PP), necessitating formulation strategies. Here, a docking-guided approach is employed to engineer intranasal mixed micelles for improved intranasal delivery and potential brain targeting. Molecular docking identifies D-α-tocopheryl polyethylene glycol succinate (TPGS) as the primary interacting excipient (ΔG = −4.0 kcal mol<sup>−1</sup>), while Tween 80 provides complementary interactions enabling cooperative micellization. The optimized PP-loaded mixed micelles (PP-MM), developed via a 3<sup>2</sup> factorial design, exhibit nanoscale size (14.97 ± 0.82 nm), narrow dispersity (PDI 0.270 ± 0.021), and efficient drug loading (4.1 ± 0.27%). The formulation demonstrates markedly enhanced in vitro release (89.3 ± 8.2% vs. 33.8 ± 2.8% at 360 min) and substantially improved ex vivo nasal permeation (66.30 ± 5.32% vs. 21.40 ± 2.21%), achieving a 2.64-fold increase in steady-state flux (compared to drug suspension). In vivo pharmacodynamic evaluation shows superior suppression of ketamine-induced hyperlocomotion (279.16 ± 18 vs. 448.33 ± 21.60 counts) without detectable neurotoxicity, supported by preserved neuronal architecture. Collectively, these findings establish docking-guided mixed micelle engineering as a robust and translational strategy to enhance solubilization, mucosal transport, and therapeutic efficacy, supporting further investigation of this scalable, non-invasive platform for intranasal delivery of poorly soluble antipsychotic agents.</p>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70162","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Dual-Targeted, pH/Reduction-Responsive Mesoporous Silica Nanocarriers for Selective Sorafenib Delivery to Hepatocellular Carcinoma 双靶向，pH/还原响应介孔二氧化硅纳米载体选择性递送索拉非尼肝细胞癌

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-29 DOI: 10.1002/adtp.202500581

Sahra Perseh, Reza Bafkary, Hossein Salmani, Mohammad Hassan Shahriari, Rassoul Dinarvand, Ismaeil Haririan, Seyedeh Sahar Mojtabazadeh, Sanaz Jamshidfar, Mohammad Akrami

{"title":"Dual-Targeted, pH/Reduction-Responsive Mesoporous Silica Nanocarriers for Selective Sorafenib Delivery to Hepatocellular Carcinoma","authors":"Sahra Perseh, Reza Bafkary, Hossein Salmani, Mohammad Hassan Shahriari, Rassoul Dinarvand, Ismaeil Haririan, Seyedeh Sahar Mojtabazadeh, Sanaz Jamshidfar, Mohammad Akrami","doi":"10.1002/adtp.202500581","DOIUrl":"https://doi.org/10.1002/adtp.202500581","url":null,"abstract":"<div>\u0000 \u0000 <p>Targeted nanocarriers offer a promising platform to improve cancer therapy by increasing efficacy while reducing off-target toxicity. A novel multilayer, reduction- and pH-responsive nanocarrier was engineered by sequentially functionalizing mesoporous silica nanoparticles with hyaluronic acid and polyamidoamine dendrimers, followed by conjugation with carboxyphenylboronic acid for dual receptor-mediated targeting of hepatocellular carcinoma cells. The nanoparticles were characterized by dynamic light scattering, showing size growth from 242.1 nm (bare) to 344.4 nm after complete coating, and a zeta potential shift from −30.1 to −7.46 mV. BET analysis confirmed preserved mesopores, with specific surface area decreasing only 1.5% from 183.2 to 180.1 m2 g<sup>−1</sup>, maintaining high porosity for drug loading. Sorafenib loading reached an encapsulation efficiency of 32% and a loading capacity of 60.4%. In vitro release demonstrated stimulus responsiveness: 55.2% release at acidic pH 5.5 and 73.4% in the presence of 10 mM glutathione, vs. 20.2% at pH 7.4 without glutathione. In HepG2 cells, the targeted system yielded an IC<sub>50</sub> of 7.6 µg/mL after 48 h, representing 1.8- and 1.25-fold improvements over sorafenib and non-targeted nanoparticles, respectively. The platform integrates HA-CD44 and carboxyphenylboronic acid with pH/redox-sensitive release for hepatocellular carcinoma therapy, offering to improve efficacy while reducing toxicity.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 8","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148616778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Injectable Self-Healing Quaternized Chitosan/Oxidized Pectin Hydrogels for Targeted siRNA Nanoparticle Delivery in Breast Cancer Therapy 用于靶向siRNA纳米颗粒递送的可注射自愈季铵化壳聚糖/氧化果胶水凝胶用于乳腺癌治疗

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-22 DOI: 10.1002/adtp.202600001

Tanawat Buntum, Nanthanit Jaruseranee, Mattaka Khongkow, Uracha Ruktanonchai, Hasan Uludağ, Orawan Suwantong

{"title":"Injectable Self-Healing Quaternized Chitosan/Oxidized Pectin Hydrogels for Targeted siRNA Nanoparticle Delivery in Breast Cancer Therapy","authors":"Tanawat Buntum, Nanthanit Jaruseranee, Mattaka Khongkow, Uracha Ruktanonchai, Hasan Uludağ, Orawan Suwantong","doi":"10.1002/adtp.202600001","DOIUrl":"https://doi.org/10.1002/adtp.202600001","url":null,"abstract":"<div>\u0000 \u0000 <p>This study explored the potential of siRNA nanoparticles-loaded quaternized chitosan and oxidized pectin (QCS/OxPec) injectable self-healing hydrogels for breast cancer therapy. The <i>SURVIVIN</i> siRNA (siSVV) nanoparticles were prepared using electrostatic interactions between siRNA, Trans-Booster, and Prime-Fect or modified polyethyleneimine (PEI). These nanoparticles exhibited significant growth inhibition and gene silencing in both breast cancer cell lines. The siSVV nanoparticles were incorporated into QCS/OxPec injectable self-healing to investigate the potential for use in breast cancer treatment. The effect of OxPec concentrations and the addition of siRNA on the properties of the hydrogels was investigated. The siSVV nanoparticles in the hydrogels showed uniform particles with spherical shapes. The siSVV nanoparticles-loaded injectable self-healing hydrogels demonstrated rapid gelation (13–18 min) with self-healing properties within 3–4 min after cutting. The extraction media from the siSVV nanoparticles loaded in the hydrogels displayed significantly different cytotoxicity to both breast cancer cells after treatment for 72 h compared with control siRNA nanoparticles and the non-treated group. Furthermore, the siSVV nanoparticles-loaded injectable self-healing hydrogels exhibited high cellular uptake within 72 h of treatment for both breast cancer cells.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Organometallic Therapeutics and Drug Delivery Strategies for Alzheimer's Disease: Bridging Metal Chemistry and Neurodegeneration 阿尔茨海默病的有机金属疗法和药物递送策略：连接金属化学和神经变性

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-20 DOI: 10.1002/adtp.70159

Ashwini Gawade, Ashwin Kuchekar, Rohini Pujari

{"title":"Organometallic Therapeutics and Drug Delivery Strategies for Alzheimer's Disease: Bridging Metal Chemistry and Neurodegeneration","authors":"Ashwini Gawade, Ashwin Kuchekar, Rohini Pujari","doi":"10.1002/adtp.70159","DOIUrl":"https://doi.org/10.1002/adtp.70159","url":null,"abstract":"<div>\u0000 \u0000 <p>Alzheimer's disease (AD) remains one of the most challenging neurodegenerative disorders to treat due to its multifactorial pathology and limited efficacy of current therapies. Although recent advances have focused on amyloid-targeting strategies, effective disease modification is hindered by poor brain penetration, unfavorable pharmacokinetics, and inability to address multiple pathological pathways simultaneously. Organometallic-based drug delivery systems have emerged as promising multifunctional platforms that combine the unique properties of metal-containing compounds with advanced nanocarrier technologies. This review highlights recent developments in organometallic therapeutics and delivery strategies for AD, focusing on pharmaceutical design, blood-brain barrier transport, controlled drug release, and neurotherapeutic potential. Various delivery platforms, including nanoparticles, liposomes, dendrimers, polymer conjugates, and metal-organic frameworks, are discussed in relation to their ability to enhance drug stability, biodistribution, targeting efficiency, and therapeutic efficacy. The therapeutic relevance of these systems is further examined through their capacity to modulate amyloid-β aggregation, oxidative stress, metal dyshomeostasis, tau pathology, and neuroinflammation. Preclinical evidence suggests that organometallic-based platforms offer advantages over conventional approaches by integrating targeted delivery with intrinsic therapeutic activity. Despite challenges related to safety, scalability, and regulatory translation, continued advances in material design and translational research may facilitate development of clinically viable disease-modifying therapies for AD.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148615212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparative Efficacy of Anti-TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience 抗肿瘤坏死因子和乌斯特金单抗治疗克罗恩病术后复发的比较疗效：10年经验

IF 3.2 4区医学

Advanced Therapeutics Pub Date : 2026-07-12 DOI: 10.1002/adtp.202500474

Zihan Chen, Jianming Lin, Xiaoling Li, Jieqing Huang, Linxin Liu, Zhirong Zeng, Xiaojun Zhuang

{"title":"Comparative Efficacy of Anti-TNF Agents and Ustekinumab for Postoperative Recurrence in Crohn's Disease: 10 Years of Experience","authors":"Zihan Chen, Jianming Lin, Xiaoling Li, Jieqing Huang, Linxin Liu, Zhirong Zeng, Xiaojun Zhuang","doi":"10.1002/adtp.202500474","DOIUrl":"https://doi.org/10.1002/adtp.202500474","url":null,"abstract":"<div>\u0000 \u0000 <p>Anti- tumor necrosis factor (TNF) agents are effective in preventing and treating postoperative recurrence (POR) in Crohn's disease (CD), while some patients have intolerance or fail treatment. Ustekinumab may offer an alternative, though data are limited. To compare the efficacy of anti-TNF agents with ustekinumab for preventing and treating POR in CD. Patients who initiated anti-TNF agents or ustekinumab within three months after surgery for POR prevention or after ileocolonoscopy with Rutgeerts score ≥ i2 for POR treatment were included. Endoscopic and clinical outcomes were evaluated. For preventing POR, 68 patients received anti-TNF agents and 34 received ustekinumab, showing no significant differences in endoscopic POR (<i>p</i> = 0.777). Ustekinumab had a lower rate of clinical POR (<i>p</i> = 0.004) and biological therapy discontinuation (<i>p</i> < 0.001). For treating POR, 35 received anti-TNF agents and 27 received ustekinumab, with no significant differences in endoscopic improvement (<i>p</i> = 0.632) or remission (<i>p</i> = 0.285). Ustekinumab showed a higher clinical treatment success (<i>p</i> = 0.004). Among 12 patients switching to ustekinumab after anti-TNF failure, 41.7% showed endoscopic remission, and 83.3% achieved clinical treatment success. Ustekinumab has better clinical outcomes and treatment persistence than anti-TNF agents in preventing and treating endoscopic POR in CD.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 7","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148466924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0